Demyelinating encephalomyelitis in a patient with renal insufficiency associated with anti-tnf therapy: adalilumab

Abstract

Given the important use of biological treatments in rheumatologic / systemic diseases in recent years, secondary alterations to them on the nervous system are currently being diagnosed mainly of an inflammatory nature that can be confused with multiple sclerosis since they are both level clinical as in very similar image. In this article we present a clinical case of a 44-year-old man who shows signs and symptoms compatible with cerebral demyelinating disease in relation to an Anti TNF-a called Adalimumab in the context of an ankylosing spondylitis resistant to infliximab after 4 years of biological treatment.